EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: A potential mechanism of EGFR-driven antagonism of apoptosis
Open Access
- 9 March 2011
- journal article
- Published by Springer Nature in Molecular Cancer
- Vol. 10 (1) , 26
Abstract
Background: Epidermal growth factor receptor (EGFR) plays an essential role in normal development, tumorigenesis and malignant biology of human cancers, and is known to undergo intracellular trafficking to subcellular organelles. Although several studies have shown that EGFR translocates into the mitochondria in cancer cells, it remains unclear whether mitochondrially localized EGFR has an impact on the cells and whether EGFRvIII, a constitutively activated variant of EGFR, undergoes mitochondrial transport similar to EGFR.Results: We report that both receptors translocate into the mitochondria of human glioblastoma and breast cancer cells, following treatments with the apoptosis inducers, staurosporine and anisomycin, and with an EGFR kinase inhibitor. Using mutant EGFR/EGFRvIII receptors engineered to undergo enriched intracellular trafficking into the mitochondria, we showed that glioblastoma cells expressing the mitochondrially enriched EGFRvIII were more resistant to staurosporine- and anisomycin-induced growth suppression and apoptosis and were highly resistant to EGFR kinase inhibitor-mediated growth inhibition.Conclusions: These findings indicate that apoptosis inducers and EGFR-targeted inhibitors enhance mitochondrial translocalization of both EGFR and EGFRvIII and that mitochondrial accumulation of these receptors contributes to tumor drug resistance. The findings also provide evidence for a potential link between the mitochondrial EGFR pathway and apoptosis.Keywords
This publication has 52 references indexed in Scilit:
- EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activityCancer Letters, 2010
- Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling AxesMolecular Cancer Research, 2010
- Epidermal Growth Factor Receptor Translocation to the MitochondriaJournal of Biological Chemistry, 2009
- A Novel Splice Variant of GLI1 That Promotes Glioblastoma Cell Migration and InvasionCancer Research, 2009
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034Journal of Clinical Oncology, 2009
- Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancerMolecular Carcinogenesis, 2008
- Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and AlkylatorsClinical Cancer Research, 2008
- Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene ExpressionCancer Research, 2007
- Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene ExpressionMolecular Biology of the Cell, 2007